Trials / Completed
CompletedNCT00277498
A 12-week, Randomized, Double-masked, Parallel Group Comparison of Evening Dosing With Xalacom in Subjects With Glaucoma
A 12-Week, Randomized, Double-Masked, Parallel Group Comparison Of Xalacom Given In The Evening, Xalatan Given In The Evening, And Timolol Given In The Morning In Patients With Open Angle Glaucoma Or Ocular Hypertension In The United States.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 528 (planned)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To demonstrate statistical superiority of the combination of latanoprost and timolol to the individual therapy of latanoprost and timolol based on intraocular pressure measurements at 8 AM, 10 AM, 4 PM at weeks 2, 6 and 12.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Xalacom | |
| DRUG | Xalatan | |
| DRUG | Timolol |
Timeline
- Start date
- 2005-12-01
- Completion
- 2007-06-01
- First posted
- 2006-01-16
- Last updated
- 2021-02-18
Locations
64 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00277498. Inclusion in this directory is not an endorsement.